Gastrointestinal Stromal Tumor: Experience in the Treatment of Localized and Advanced Disease at the Clinical Hospital of Parana Federal University

Authors

  • Karina Costa Maia Vianna Universidade Federal do Paraná (UFPR). Curitiba (PR), Brasil.
  • Sérgio Lunardon Padilha Universidade Federal do Paraná (UFPR). Curitiba (PR), Brasil.
  • Bianca Ramos Ferronatto Universidade Federal do Paraná (UFPR). Curitiba (PR), Brasil.
  • Lucas Fernando Uratani Universidade Federal do Paraná (UFPR). Curitiba (PR), Brasil.
  • Felipe Augusto Santiago de Almeida Universidade Federal do Paraná (UFPR). Curitiba (PR), Brasil.
  • José Zanis Neto Universidade Federal do Paraná (UFPR). Curitiba (PR), Brasil.

DOI:

https://doi.org/10.32635/2176-9745.RBC.2012v58n1.635

Keywords:

Gastrointestinal Stromal Tumors, Antineoplastic Agents/therapeutic use, Mesylates, Proto-Oncogene Proteins c-kit, Immunohistochemistry, Retrospective Studies

Abstract

Introduction: Gastrointestinal stromal tumors (GIST ) are rare neoplasms that originate from interstitial cells of Cajal. Objectives: To describe the experience at the Curitiba Clinical Hospital in the treatment of both localized and advanced GIST, with analysis of clinical and anatomical and pathological characteristics and use of imatinib. Methodology: A retrospective study of 32 patients diagnosed for immunohistochemistry, c-Kit positive, from 2003 to 2008. Results: The median age was 66 years, the median tumor size was 8.4 cm and the most common sites were the tomach in 46.9% and the small intestine in 40.9%. Patients at high risk of progressive disease: 37.5%. 23 patients had localized disease at diagnosis, 39.1% relapsed, and 9 patients had advanced disease. The median follow up was 43.7 months, overall survival at 5 years for the total group of 56.2%. In localized disease, overall survival at 5 years was 73.8% and 37.5% in advanced disease (p=0.03). There was no impact of prognostic factors on survival. The use of imatinib occurred in 16 patients, 43.8% due to initial metastasis, 37.5% disease progression, 12.5% local recurrence and 6.2% compromised margins. The median overall survival with the use of imatinib was 53 months and the first progression-free survival of 32.9 months. There was good tolerance to imatinib and only two patients received sunitinib. Conclusion: Predominant tumors were large, gastric-sited and of high risk of progression. The relapse rate was high in localized disease. And overall survival of patients with localized disease and who used the imatinib was considered satisfactory.

 

Downloads

Download data is not yet available.

Published

2012-03-30

How to Cite

1.
Vianna KCM, Padilha SL, Ferronatto BR, Uratani LF, Almeida FAS de, Zanis Neto J. Gastrointestinal Stromal Tumor: Experience in the Treatment of Localized and Advanced Disease at the Clinical Hospital of Parana Federal University. Rev. Bras. Cancerol. [Internet]. 2012 Mar. 30 [cited 2024 Dec. 23];58(1):47-56. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/635

Issue

Section

ORIGINAL ARTICLE

Most read articles by the same author(s)